Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

FDA clears IND application for BXCL-501 for the treatment of opioid withdrawal symptoms

Feb. 6, 2020

Alkermes Pharma presents new naltrexone prodrugs for drug dependency

Feb. 5, 2020

Nr4a1 regulates gene transcription during cocaine abstinence: a potential target against addiction

Feb. 4, 2020

Naltrexone prodrugs synthesized at Alkermes

Jan. 31, 2020

Cerevel starts dosing volunteers in phase I study of CVL-936

Jan. 31, 2020

Snake venom organoid gives toxin insights

Jan. 30, 2020

Idorsia Pharmaceuticals discovers OX1/OX2 receptor antagonists

Jan. 29, 2020

Results from GLP preclinical study of AAV8-hCocH gene therapy

Jan. 22, 2020

Cobra genome may yield new antivenoms, venom-based drugs

Jan. 8, 2020

Opiant signs letter of intent with NCATS to collaborate on OPNT-004 development

Jan. 3, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...